Active Clinical Research for Hepatocellular, Liver and Lung Cancer

Comprehensive Cancer Centers runs Phase II and Phase III research trials for the following Hepatocellular, liver and lung cancers:

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations **COHORT A- CLOSED TO ENROLLMENT; COHORTS B (2 SLOTS REMAINING) AND C (3 SLOTS OPEN)- CONTACT MONITOR FOR SLOT; COHORT D ON HOLD TO ENROLLMENT DUE TO INTERIM ANALYSIS**
Study#: i3211
Contact Us: For information about this clinical study, Email Us.

SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing FirstLine Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression.
Study#: i3292
Contact Us: For information about this clinical study, Email Us.

A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)
Study#:i3321
Contact Us: For information about this clinical study, Email Us.

Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
Study#:i3371
Contact Us: For information about this clinical study, Email Us.

An International Phase 3, Double-Blind, Randomized Study to Evaluate Efficacy and Safety of PF-08634404 (SSGJ-707) in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Study#:SCRI: 25156 (PENDING)
Contact Us: For information about this clinical study, Email Us.

Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Nivolumab and Docetaxel Versus Docetaxel Monotherapy in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Study#:i3394
Contact Us: For information about this clinical study, Email Us.